Cover Image
市場調查報告書

在製藥·生物科技企業的臨床階段的合作契約和條件

Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2016

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 121244
出版日期 內容資訊 英文 1,000+ Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
在製藥·生物科技企業的臨床階段的合作契約和條件 Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2016
出版日期: 2016年10月05日 內容資訊: 英文 1,000+ Pages
簡介

本報告提供全球主要醫療保健企業的臨床階段合作契約締結趨勢的相關調查,提供契約概要和目的,支付條件,契約·疾病·各技術類型的合作契約數量趨勢,代表性案例(案例研究),相關企業的一覽,契約的目錄(全2000件以上)等彙整資料,為您概述為以下內容。

摘要整理

第1章 簡介

第2章 位於臨床階段的化合物相關契約簽訂的理由

  • 簡介
  • 在臨床階段的合作所扮演的角色
    • 臨床階段界內許可證
    • 在臨床階段的轉出授權
  • 第I∼III代交易的差異
  • 在臨床階段簽訂合作契約的理由
    • 授權方面的理由
    • 許可證取得方面的理由
  • 在臨床階段的合作契約未來性

第3章 在臨床階段的交易策略與結構

  • 簡介
  • 各企業在哪個階段簽訂合作契約?
    • 在臨床早期的製藥/生物科技企業的合作
      • 在藥物研發·前臨床階段締結的案例研究(全4件)
    • 在臨床後期的製藥/生物科技企業的合作
      • 在臨床實驗階段締結的案例研究(全4件)
  • 在臨床早期·後期的合作:風險/成本比較
  • 在臨床階段締結的支出額
  • 專門/複合契約的差異
  • 專門授權合約結構
    • 代表性案例(計2件)
  • 在臨床階段的複合合作契約
    • 代表性案例(計1件)

第4章 在臨床階段的合作付款策略

  • 簡介
  • 在臨床階段的付款策略
  • 付款的選擇

第5章 在臨床階段的契約締結的趨勢

  • 簡介
  • 在近幾年臨床階段的合作趨勢
    • 在第一階段的合作趨勢
    • 在第二階段的合作趨勢
    • 在第三階段的合作趨勢
  • 大型製藥企業的契約締結活動
  • 大生物科技企業的契約締結活動
  • 在臨床階段的合作趨勢:各交易類型
  • 在臨床階段的合作趨勢:各疾病類型
  • 合作趨勢:臨床階段的技術種類別

第6章 在臨床階段的合作契約平均付款條件

  • 簡介
  • 在臨床階段的付款條件的指南
    • 預付款
    • 階段性付款
    • 品牌忠誠度支付
  • 在臨床階段的付款條件:契約資料分析
    • 公共資料
    • 調查資料
  • 付款條件分析
    • 在臨床階段的契約總額
    • 在臨床階段的預付款
    • 在臨床階段的階段性付款
    • 在臨床階段的權利金費率

第7章 代表性臨床階段的契約

  • 簡介
  • 在主要的臨床階段的契約:各金額

第8章 在大製藥/生物科技企業臨床階段的合作契約

  • 簡介
  • 大製藥/生物科技企業的,在臨床階段的合作契約活用方法
  • 大型製藥企業簡介(全50公司)
  • 大生物科技簡介(全47公司)

第9章 在臨床階段的合作契約一覽

  • 簡介
  • 企業一覽(ABC順序)
  • 各契約類型
  • 各開發階段
  • 各治療領域

第10章 在臨床階段的契約締結:各開發階段趨勢

  • 簡介
  • 臨床實驗的各階段的交易趨勢
    • 第一階段
    • 第二階段
    • 第三階段

Wildwood 關於Ventures

附錄

  • 簡介
  • 附錄1 在臨床階段的契約的一覽:各企業(ABC順序),2007∼2013年
  • 附錄2 在臨床階段的契約的一覽:各契約類型,2007∼2013年
  • 附錄3 在臨床階段的契約的一覽:各治療領域,2007∼2013年
  • 附錄4 抗體相關的合作:資源中心
  • 線上合作
  • 合作趨勢
  • 相關調查

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2058

The ‘Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2016 ’ report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of over 2,000 clinical stage partnering deals announced since 2010 including financial terms where available including numerous links to online deal records of actual clinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of clinical stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner clinical stage compounds/products.

Chapter 3 provides an overview of clinical stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in clinical stage deals.

Chapter 5 provides a review of clinical stage deal making since 2010. Deals activity is reviewed by year, stage of development at signing, therapeutic area, technology type, as well as most active dealmakers.

Chapter 6 provides a detailed analysis of clinical stage payment terms including headline, upfront, milestone and royalty rates for phase I, phase II and phase III deals.

Chapter 7 provides a review of the leading clinical stage deal by headline value. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 8 provides a comprehensive listing of the top 50 most active clinical stage dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 9 provides a comprehensive and detailed review of clinical stage partnering deals signed and announced since 2010, where a contract document is available in the public domain.

Chapter 10 provides a comprehensive directory of clinical stage partnering deals since 2010 organized by stage of development - phase I, phase II and phase III.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous tables and figures that illustrate the trends and activities in clinical stage partnering and deal making since 2010.

In addition, a comprehensive appendix of all clinical stage deals since 2010 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of clinical stage products and compounds.

Key benefits

‘Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2016 ’ provides the reader with the following key benefits:

  • In-depth understanding of clinical stage deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of clinical stage agreements with numerous real life case studies
  • Insight into the terms included in a clinical stage agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

‘Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2016 ’ is intended to provide the reader with an in-depth understanding and access to clinical stage deal trends and structure of deals entered into by leading companies worldwide.

‘Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2016 ’ includes:

  • Trends in clinical stage dealmaking in the biopharma industry since 2010
  • Analysis of clinical stage deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life clinical stage deals
  • Access to over 2,000 clinical stage deals
  • The leading clinical stage deals by value since 2010
  • Most active clinical stage dealmakers since 2010
  • The leading clinical stage partnering resources

In ‘Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2016 ’, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal type
  • Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2016 ’report provides comprehensive access to available deals and contract documents for over 2,000 clinical stage deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner clinical stage compounds?

  • 2.1. Introduction
  • 2.2. The role of clinical stage partnering
    • 2.2.1. In-licensing at clinical stage
    • 2.2.2. Out-licensing at clinical stage
  • 2.3. Difference between phase I, II and III stage deals
  • 2.4. Reasons for entering into clinical stage partnering deals
    • 2.4.1. Licensors reasons for entering clinical stage deals
    • 2.4.2. Licensees reasons for entering clinical stage deals
  • 2.5. The future of clinical stage partnering deals

Chapter 3 - Clinical stage deal strategies and structure

  • 3.1. Introduction
  • 3.2. At what stage do companies partner?
    • 3.2.1. Partnering early in pharmaceutical/biotech
      • 3.2.1.1. Discovery and preclinical stage partnering case studies
        • 3.2.1.1.a. Case study: LEO Pharma - 4SC
        • 3.2.1.1.b. Case study: Heptares Therapeutics - Cubist
        • 3.2.1.1.c. Case study: Incyte - Agenus Bio
        • 3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec
    • 3.2.2. Partnering later in pharmaceutical/biotech
      • 3.2.2.1. Clinical stage partnering case studies
        • 3.2.2.1.a. Case study: Servier - GeNeuro
        • 3.2.2.1.b. Case study: Teva - Xenon Pharmaceuticals
        • 3.2.2.1.c. Case study: AstraZeneca - Ardelyx
        • 3.2.2.1.d. Case study: Baxter - Onconova Therapeutics
  • 3.3. Early and later stage partnering - a risk/cost comparison
  • 3.4. What do companies spend on clinical stage partnering?
  • 3.5. Pure versus multi-component partnering deals
  • 3.6. Pure licensing agreement structure
    • 3.6.1. Example pure licensing agreements
      • 3.6.1.a. Case study : Argos Therapeutics - Medinet
      • 3.6.1.b. Case study : Pfizer - GlycoMimetics
  • 3.7. Multicomponent clinical stage partnering agreements
    • 3.7.1. Example multicomponent clinical stage clauses
      • 3.7.1.a. Case study: Gilead Sciences - GlobeImmune

Chapter 4 - Clinical stage partnering payment strategies

  • 4.1. Introduction
  • 4.2. Clinical stage payment strategies
  • 4.3. Payment options
    • 4.3.1. Headline values
    • 4.3.2. Upfront payments
      • 4.3.2.1. Conditionality of upfront payments
    • 4.3.3. Loans
    • 4.3.4. Convertible loans
    • 4.3.5. Equity
    • 4.3.6. R&D funding
    • 4.3.7. Licensing fees
    • 4.3.8. Milestone payments
    • 4.3.9. Royalty payments
      • 4.3.9.1. Issues affecting royalty rates
      • 4.3.9.2. Royalties on combination products
        • 4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech
      • 4.3.9.3. Guaranteed minimum/maximum annual payments
      • 4.3.9.4. Royalty stacking
      • 4.3.9.5. Royalties and supply/purchase contracts
    • 4.3.10. Quids
    • 4.3.11. Option payments

Chapter 5 - Trends in clinical stage deal making

  • 5.1. Introduction
  • 5.2. Clinical stage partnering over the years
    • 5.2.1. Trends in phase I deals since 2010
      • 5.2.1.1. Attributes of phase I deals
    • 5.2.2. Trends in phase II deals since 2010
      • 5.2.2.2. Attributes of phase II deals
    • 5.2.3. Trends in phase III deals since 2010
      • 5.2.3.1. Attributes of phase III deals
  • 5.3. Clinical stage partnering by deal type
  • 5.4. Clinical stage partnering by disease type
  • 5.5. Partnering by clinical stage technology type
  • 5.6. Clinical stage partnering by most active company, 2010 to 2016

Chapter 6 - Payment terms for clinical stage partnering

  • 6.1. Introduction
  • 6.2. Guidelines for clinical stage payment terms
    • 6.2.1. Upfront payments
    • 6.2.2. Milestone payments
    • 6.2.3. Royalty payments
  • 6.3. Clinical stage payment terms - deal data analysis
    • 6.3.1. Public data
    • 6.3.2. Survey data
  • 6.4. Payment terms analysis
    • 6.4.1. Clinical stage partnering headline values
    • 6.4.2. Clinical stage deal upfront payments
    • 6.4.3. Clinical stage deal milestone payments
    • 6.4.4. Clinical stage royalty rates
  • 6.5 Clinical stage median financials
    • 6.5.1. Clinical stage headline value
    • 6.5.2. Clinical stage upfront value
    • 6.5.3. Clinical stage milestone value
    • 6.5.4. Clinical stage royalty value

Chapter 7 - Leading clinical stage deals

  • 7.1. Introduction
  • 7.2. Top clinical stage deals by value

Chapter 8 - Top 50 most active clinical stage dealmakers

  • 8.1. Introduction
  • 8.2. Top 50 most active clinical stage dealmakers

Chapter 9 - Clinical stage partnering contracts directory

  • 9.1. Introduction
  • 9.2. Clinical stage deals with contracts 2010 to 2016

Chapter 10 - Clinical stage deal making by development stage

  • 10.1. Introduction
  • 10.2. Deals by clinical stage
    • Phase I
    • Phase II
    • Phase III
    • Regulatory
    • Formulation

Appendices

Appendix 1 - Clinical stage dealmaking by companies A-Z

Appendix 2 - Clinical stage dealmaking by industry sector

Appendix 3 - Clinical stage dealmaking by stage of development

Appendix 4 - Clinical stage dealmaking by therapy area

Appendix 5 - Clinical stage dealmaking by technology type

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Definition of clinical phases in dealmaking
  • Figure 2: Agreements signed by phase of development (2010- 2016), % of all deals
  • Figure 3: Components of the pure licensing deal structure
  • Figure 4: Payment options for clinical stage partnering deals
  • Figure 5: Issues affecting royalty rates
  • Figure 6: Clinical stage partnering frequency 2010- 2016
  • Figure 7: Phase I clinical stage partnering since 2010
  • Figure 8: Phase II clinical stage partnering since 2010
  • Figure 9: Phase III clinical stage partnering since 2010
  • Figure 10: Clinical stage partnering by deal type since 2010
  • Figure 11: Clinical stage partnering by disease type since 2010 80
  • Figure 12: Clinical stage partnering by technology type since 2010
  • Figure 13: Top 50 most active clinical stage dealmakers, 2010 to 2016
  • Figure 14: Review of upfront payments for clinical stage deals
  • Figure 15: Review of milestone payments for clinical stage deals
  • Figure 16: Review of royalty payments for clinical stage deals
  • Figure 17: Clinical stage deals with a headline value
  • Figure 18: Clinical stage deals with an upfront value
  • Figure 19: Clinical stage deals with a milestone value
  • Figure 20: Clinical stage deals with a royalty rate value
  • Figure 21: Summary median headline value by clinical stage of development, 2010-2016
  • Figure 22: Summary median upfront payments by clinical stage of development, 2010-2016
  • Figure 23: Summary median milestone payments by stage of development, 2010-2016
  • Figure 24: Summary median royalty rate by stage of development, 2010-2016
  • Figure 25: Top clinical stage deals by value since 2010
  • Figure 26: Most active clinical stage dealmakers 2010 to 2016
Back to Top